Expression of Her-2/neu and Bcl-2 in patients with non-small cell lung cancer Source: International Congress 2017 – Gene signatures in bronchial diseases Year: 2017
Survivin expression in non-small cell lung cancer Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases Year: 2010
p53 and mdm2 expression in nonsmall cell lung cancer (NSCLC): the lack of prognostic relevance Source: Eur Respir J 2001; 18: Suppl. 33, 230s Year: 2001
Ki-67 in non-small cell lung cancer Source: Annual Congress 2012 - New results in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease Year: 2012
p-53 and HER2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer Source: Annual Congress 2007 - Novel genetic markers in pathology Year: 2007
Prognostic value of p21 protein expression in non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 674s Year: 2004
Her/2 neu and p53 expression in patients with non-small cell lung cancer predict shortened survival Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010
The prognostic value of altered pRb and p53 protein expression in non-small cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 363s Year: 2003
Prognostic significance of p53 and bcl-2 abnormalities in operable non-small cell lung cancer Source: Eur Respir J 2001; 17: 660-666 Year: 2001
Expression of ERCC1 in normal and tumor tissues in non-small cell lung cancer Source: Annual Congress 2007 - Biology of thoracic malignancies Year: 2007
An analysis of EGFR expression and tumour imaging in non-small cell carcinomas of lung Source: Annual Congress 2011 - Imaging, functional evaluation and staging for lung cancer patients Year: 2011
The association of p53 and p21 expression with clinicopathological parameters and prognosis in non-small cell lung cancer Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010
The efficacy of Ado-trastuzumab emtansine in HER-2 aberrant non-small cell lung cancer Source: International Congress 2019 – Thoracic oncology: Treatment, diagnostic options and biology Year: 2019
FGFR1 gene aberrations and FGFR1 protein expression in squamous non-small cell lung cancer (Sq-NSCLC). Source: Virtual Congress 2021 – Biology of lung cancer: preclinical and translational research Year: 2021
Clinical relevance of p53 and K-ras mutations in nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 230s Year: 2001
K-RAS oncogenic mutations in patients with nonsmall cell lung cancer Source: Annual Congress 2007 - Biology of thoracic malignancies Year: 2007
Mutant P53 expression in squamous cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 72s Year: 2002
MDM-2 gene amplification is associated with poor prognosis in operable non-small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 596s Year: 2002
The value of CD44 and MMP-2 expression in non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 77s Year: 2004
Expression of Fhit protein in non-small cell lung cancer (NSCLC) and its correlation with Ki-67, a proliferative marker Source: Eur Respir J 2002; 20: Suppl. 38, 230s Year: 2002